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Microbial biofilms strongly resist host immune responses and antimicrobial treatments
and are frequently responsible for chronic infections in peri-implant tissues.
Biosurfactants (BSs) have recently gained prominence as a new generation of anti-
adhesive and antimicrobial agents with great biocompatibility and were recently
suggested for coating implantable materials in order to improve their anti-biofilm
properties. In this study, the anti-biofilm activity of lipopeptide AC7BS, rhamnolipid
R89BS, and sophorolipid SL18 was evaluated against clinically relevant fungal/bacterial
dual-species biofilms (Candida albicans, Staphylococcus aureus, Staphylococcus
epidermidis) through quantitative and qualitative in vitro tests. C. albicans–S. aureus
and C. albicans–S. epidermidis cultures were able to produce a dense biofilm on the
surface of the polystyrene plates and on medical-grade silicone discs. All tested BSs
demonstrated an effective inhibitory activity against dual-species biofilms formation in
terms of total biomass, cell metabolic activity, microstructural architecture, and cell
viability, up to 72 h on both these surfaces. In co-incubation conditions, in which BSs
were tested in soluble form, rhamnolipid R89BS (0.05 mg/ml) was the most effective
among the tested BSs against the formation of both dual-species biofilms, reducing on
average 94 and 95% of biofilm biomass and metabolic activity at 72 h of incubation,
respectively. Similarly, rhamnolipid R89BS silicone surface coating proved to be the
most effective in inhibiting the formation of both dual-species biofilms, with average
reductions of 93 and 90%, respectively. Scanning electron microscopy observations
showed areas of treated surfaces that were free of microbial cells or in which thinner
and less structured biofilms were present, compared to controls. The obtained results
endorse the idea that coating of implant surfaces with BSs may be a promising strategy
for the prevention of C. albicans–Staphylococcus spp. colonization on medical devices,
and can potentially contribute to the reduction of the high economic efforts undertaken
by healthcare systems for the treatment of these complex fungal–bacterial infections.
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INTRODUCTION
Biofilms are complex biological structures, composed of sessile
multicellular communities encapsulated in a hydrated matrix of
polysaccharides and proteins, in which microorganisms become
more resistant to drug therapy and host immune response (Chen
and Wen, 2011; Pompilio and Di Bonaventura, 2018). Microbial
cells forming biofilms also communicate through the quorum
sensing (QS) system, which is responsible of regulating genes
expression, production of proteases and other signals that enable
high-density bacterial cluster to flourish (Buch et al., 2019;
Irorere et al., 2019).
Biofilms give rise to chronic infections both in tissues (e.g.,
lung infection in cystic fibrosis, chronic wound infections)
and on the surface of implantable medical devices (e.g.,
orthopedic prostheses, endotracheal tubes, intravenous and
urinary catheters, heart valves), which are characterized by the
development of persistent and progressive diseases mainly due to
the inflammatory response surrounding these biofilms (Clinton
and Carter, 2015; Percival et al., 2015; Teo et al., 2016; Omar
et al., 2017; Song et al., 2018). This makes many biofilm infections
difficult to diagnose or to adequately treat.
Although most tissue and medical device-associated
infections are caused by a single pathogen, an increasing
number of polymicrobial infections have been reported in the
clinical practice (Mihai et al., 2015; Rodrigues et al., 2019).
The involved microorganisms are believed to coexist and
realize synergistic interactions within the biofilm environment
resulting in enhanced pathogenicity, virulence, and resistance
to antimicrobials, thus leading to more aggressive forms of
infections (Marculescu and Cantey, 2008; Burmølle et al.,
2014). An emerging finding in polymicrobial biofilm research
is the presence of both eukaryotic and prokaryotic pathogens
(Brogden et al., 2005). The coexistence of Candida albicans
and Staphylococcus species, in particular, has been frequently
associated with extremely complicated infections and high
mortality rates (Tsui et al., 2016). Biofilm-associated diseases
related to C. albicans and Staphylococcus species, including
wound infections, periodontitis, denture stomatitis, and medical
devices related infections involving catheters and orthopedic
implants have all been described before (Adam et al., 2002; Gupta
et al., 2005; Valenza et al., 2008; Cuesta et al., 2010; Harriott
and Noverr, 2011). These polymicrobial infections are difficult
to diagnose and are mostly untreatable with the conventional
antibiotic treatment strategies and commonly requires complex
multi-drug therapy and in the vast majority of cases, the removal
of infected medical devices (Harriott and Noverr, 2009; Pammi
et al., 2013; Carolus et al., 2019).
This worldwide public health problem requires the
development of innovative approaches able to efficiently
tackle infections associated with these bacteria, fungi, and their
biofilms. For this reason, several surface-coating strategies have
been proposed to safeguard medical devices from microbial
adhesion and colonization (John et al., 2007; Zilberman and
Elsner, 2008; Ramasamy and Lee, 2016; Francolini et al., 2017;
Khatoon et al., 2018; Wang and Tang, 2018; Ghensi et al., 2019).
Unfortunately, surface-treated biomaterials showed, in some
cases, limited efficacy over time as well as an inherent risk of
cytotoxicity toward cell tissues (Francolini and Donelli, 2010).
Therefore, the application of natural molecules for the creation
of new safe and effective biocompatible antibacterial and/or
anti-adhesive biomaterial coatings or pharmaceutical products to
prevent and treat both single-species and polymicrobial biofilm
infections are urgently required (Vasilev et al., 2011).
Focusing on this goal, biosurfactants (BSs) have been
suggested as a new group of antimicrobial/anti-biofilm
biocompatible compounds useful in a wide range of
pharmaceutical and biomedical applications (Diaz De Rienzo
et al., 2014; Elshikh et al., 2017; Lydon et al., 2017; Juma et al.,
2020). BSs are amphiphilic molecules, produced by a wide group
of microorganisms, which partition at and alter the physical–
chemical conditions of the interfaces and are characterized by
interesting biological activities like antimicrobial, anti-adhesive,
and anti-biofilm properties (Banat et al., 2014; Simms et al.,
2020). BSs ability to destabilize the integrity and permeability of
cell membranes and to modify surface properties of biomaterials,
affecting microbial vitality and adhesion, limiting biofilm
formation, or reducing the structural integrity of existing
biofilms have been reported (Fracchia et al., 2015, 2019;
Satpute et al., 2016).
Toward this goal, during the past few years, we have
demonstrated the ability of lipopeptides, rhamnolipids, and
sophorolipids BSs, alone or in combination with antimicrobials
and quorum-sensing molecules to inhibit microbial adhesion and
biofilm formation of mono-species biofilms of fungal or bacterial
pathogens on biomedical materials such as silicone (Ceresa et al.,
2016, 2017, 2018, 2019b, 2020). The activity of BSs against biofilm
formation on model surfaces such as polystyrene, glass, silicone,
and polydimethylsiloxane has also been described in other works
(Sharma and Saharan, 2016; Aleksic et al., 2017; Janek et al., 2018;
Satpute et al., 2018). Conversely, to our knowledge, no studies
have been conducted yet concerning the use of BSs against these
clinically relevant fungal–bacterial polymicrobial biofilms.
In this perspective, the present study aimed at testing the
efficacy of three different BSs (lipopeptide AC7BS, rhamnolipid
R89BS, and sophorolipid SL18) as anti-adhesive and anti-biofilm
agents against the formation of clinically relevant multi-species
biofilms composed by fungal and bacterial species (C. albicans–
Staphylococcus aureus, C. albicans–Staphylococcus epidermidis)
employing a multidisciplinary and multifaceted approach.
MATERIALS AND METHODS
Study Design
The study was organized in seven experimental phases: (1)
definition of the dual-species biofilm model with quantification
of biomass production and metabolic activity on polystyrene and
silicone elastomer and comparison with the corresponding single
species counterpart; (2) identification of the non-cytotoxic BSs
concentrations with a significant inhibitory activity against single
species biofilm formation; (3) evaluation of the anti-biofilm and
antimicrobial activity of BSs at the non-cytotoxic concentrations
against polymicrobial cultures, in co-incubation; (4) evaluation
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of the anti-biofilm and antimicrobial activity of silicone discs
coated with BSs against polymicrobial cultures; (5) assessment of
cells surface hydrophobicity and membrane permeability changes
induced by BSs in soluble form; (6) observation of the dual-
species biofilm micro-structure on BSs-coated silicone discs;
and (7) preliminary assessment of BSs-coated silicone discs
biocompatibility.
Strains
The rhamnolipid-producer strain Pseudomonas aeruginosa 89, a
clinical isolate from a patient with cystic fibrosis, was cultured
from frozen stocks onto Tryptic Soy Agar (TSA, Scharlab,
Barcelona, ES) at 37◦C for 18–20 h. The lipopeptide-producer
strain Bacillus subtilis AC7, from the inside of stems of Robinia
pseudoacacia, was cultured from frozen stocks onto Luria Bertani
agar (LBA, Sigma–Aldrich, St. Louis, MO, United States) at
28◦C for 18–20 h. The sophorolipid-producer strain Candida
bombicola ATCC 22214, obtained from the American Type
Culture Collection (ATCC, Manassas, VA, United States), was
cultured from frozen stocks onto Sabouraud dextrose agar (SDA,
Scharlab, Barcelona, ES) at 25◦C for 18–20 h. All the biofilm-
producer strains used in this study were obtained from the ATCC
(Manassas, VA, United States). C. albicans ATCC 10231, S. aureus
ATCC 25923, S. aureus ATCC 6538, and S. epidermidis ATCC
35984 were cultured from frozen stocks onto SDA and TSA
plates, respectively, and incubated overnight at 37◦C.
Biosurfactants Production and
Extraction
Lipopeptide AC7BS and rhamnolipid R89BS were produced and
extracted as described by Ceresa et al. (2018, 2019b). Briefly, a
loop of B. subtilis AC7 from a LBA overnight culture was grown
in 20 ml of LB broth at 28◦C for 4 h at 140 r/min. Afterward, 2 ml
of this culture was used to inoculate 500 ml of LB broth and was
incubated at 28◦C for 24 h at 140 r/min. A loop of P. aeruginosa
89 from a TSA overnight culture was grown in 40 ml of Nutrient
Broth II (Sifin Diagnostics GmbH, Berlin, DE) for 4 h at 37◦C at
140 r/min. Afterward, 8 ml of this culture was added to 400 ml
of Siegmund–Wagner medium and incubated at 37◦C for 5 days
at 120 r/min. Cell-free supernatants were acidified to pH 2.2
with 6 M HCl (AC7BS) or 6 M H2SO4 (R89BS) and stored
overnight at 4◦C. Lipopeptide AC7BS and rhamnolipid R89BS
were extracted three times with 167 ml ethyl acetate:methanol
(4:1) or 134 ml ethyl acetate (Sigma–Aldrich, St. Louis, MO,
United States), respectively. Organic phases were anhydrified,
filtrated, and vacuum-dried. BSs were recovered by dissolution
in acetone (Sigma–Aldrich, St. Louis, MO, United States) and
collected in glass tubes. Acetone was, then, evaporated and
BSs were weighted.
Sophorolipid SL18 was obtained from a fed batch cultivation
of C. bombicola ATCC 22214, according to Ceresa et al. (2020).
Briefly, the cells (10% v/v) were grown in 2 l of Glucose Yeast
Urea (GYU) medium [100 g/l glucose (Sigma–Aldrich, St. Louis,
MO, United States), 10 g/l yeast extract (Sigma–Aldrich, St.
Louis, MO, United States), and 1 g/l urea (Sigma–Aldrich, St.
Louis, MO, United States)]. Oleic acid (99%, Sigma–Aldrich,
St. Louis, MO, United States) was supplemented as a feeding
source at a concentration of 20% to generate lactonic congeners.
Fermentation was performed for 8 days at 200 r/min and
30◦C. Sophorolipid SL18 were, then, extracted twice with
ethyl acetate (1:1 extract ratio) (Sigma–Aldrich, St. Louis, MO,
United States) and partially purified by three washings with
hexane (Sigma–Aldrich, St. Louis, MO, United States) to remove
residual fatty acids.
At the end of the extraction process, the presence, the purity,
and the composition of the three BSs were confirmed by ESI/MS
analysis as previously described (Ceresa et al., 2016, 2019b, 2020).
All the following biological tests and microscopy analyses were
performed using the same batch of production for each BS. BSs
were dissolved in Phosphate Buffer Solution pH 7.4 (PBS) at
the different concentrations of use. The solutions were filtered
through a 0.2 µm filter and stored at room temperature.
Silicone Cleaning and Sterilization
Silicone-elastomeric discs (SEDs—0.8 cm in diameter and
1.5 mm in thickness) were cut from medical-grade silicone sheets
(TECNOEXTR s.r.l, Palazzolo sull’Oglio, IT) and prepared as
described in Ceresa et al. (2015). Briefly, discs were cleaned with
a 1.4% (v/v) RBSTM 50 solution (Sigma–Aldrich, St. Louis, MO,
United States), sonicated for 5 min at 60 kHz, and rinsed twice in
Milli-Q water. Silicone was, then, dipped in MeOH (99%, Sigma–
Aldrich, St. Louis, MO, United States), sonicated, and rinsed as
previously described. Afterward, SEDs were autoclaved, dried,
and moved aseptically into 48-well plates.
Anti-biofilm Assays
Mono- and dual-species biofilm formation: fungal and bacterial
cells were suspended in Roswell Park Memorial Institute (RPMI)
1640 (Sigma–Aldrich, St. Louis, MO, United States) buffered
with MOPS (Sigma–Aldrich, St. Louis, MO, United States) and
supplemented with 2% Glucose (Biolife, Monza, IT), pH 7.0
(RPMI +2%G). Cell density was adjusted up to 106 and 107
colony forming unit (CFU)/ml for C. albicans and Staphylococcus
spp. respectively. Polystyrene was used as a substrate for the
growth of biofilms in co-incubation assays and silicone was
used for the growth of biofilms in the coating assays. Surfaces
were inoculated with 0.5 ml of the suspension and incubated
at 37◦C in static conditions up to 72 h; growth medium was
removed and replaced with fresh RPMI +2%G every 24 h.
Blank polystyrene and silicone control surfaces (without biofilm)
were also included in the experimental setting. The ability of
microbial strains to form polymicrobial biofilms, compared to
the mono-species ones, was evaluated by the determination of
biofilm biomass and metabolic activity of sessile cells as described
below. All experiments were carried out in quadruplicate and
repeated two times.
Co-incubation conditions (BSs in soluble form in polystyrene
plates): in order to determine the minimum non-cytotoxic
concentration of BSs (Ceresa et al., 2018, 2019b) able to
inhibit single-species biofilm formation on polystyrene by at
least 80%, increasing concentrations of lipopeptide AC7BS
(0.125–0.5 mg/ml) and rhamnolipid R89BS (0.0125–0.05 mg/ml)
were tested. The wells were filled with 50 µl of 10× BSs
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solutions (treated samples) or with an equal volume of PBS
(control samples) and 0.5 ml of single-species suspensions of
C. albicans (106 CFU/ml) and Staphylococcus spp. (107 CFU/ml)
in RPMI +2%G. The 48-well plates were incubated for 24 h
at 37◦C. The effect was evaluated in terms of biofilm biomass
reduction as described below. All experiments were carried out
in quadruplicate and repeated twice.
Subsequently, the selected concentrations of BSs were tested
against dual-species biofilm formation. The bottom of the wells
was covered with 50 µl of the selected 10× BSs solutions
(treated samples) or with an equal volume of PBS (control
samples). Then, 0.5 ml of the dual-species suspensions of
C. albicans (106 CFU/ml) and Staphylococcus spp. (107 CFU/ml)
in RPMI +2%G were added to each well. The plates were
incubated up to 72 h at 37◦C. Growth medium was removed
and replaced with fresh RPMI +2%G supplemented with 10×
BSs solutions (treated samples) or with an equal volume of
PBS (control samples) every 24 h. Blank surfaces (without
biofilm) were also included in the experimental setting. The
ability of microbial surfactants to inhibit dual-species biofilm
formation in co-incubation conditions was evaluated by the
determination of biofilm biomass and metabolic activity of
sessile and planktonic cells as described below. Experiments were
performed in quadruplicate and repeated twice.
Coating conditions: the treatment of silicone surfaces was
carried out in 48-well plates by immersing SEDs in BS solutions
(rhamnolipid R89BS: 2 mg/ml; lipopeptide AC7BS: 2 mg/ml;
sophorolipid SL18: 8 mg/ml) at 37◦C for 24 h at 180 r/min.
These solutions were chosen as previously optimized in Ceresa
et al. (2016; 2019b; 2020). Afterward, discs were moved into
new plates and dried before use. Five hundred microliters of
the dual-species suspensions (C. albicans at the concentration
of 106 CFU/ml and Staphylococcus spp. at the concentration of
107 CFU/ml) in RPMI +2%G were added to each well. SEDs
were incubated up to 72 h at 37◦C. Every 24 h, discs were
moved into fresh media. Blank surfaces (without biofilm) were
also included. The anti-biofilm activity of BSs was evaluated at 24,
48, and 72 h by the determination of biofilm biomass, metabolic
activity of sessile and planktonic cells, and viable cell counting as
described below. Experiments were performed in quadruplicate
and repeated twice.
Biofilm Biomass
The determination of the total biomass was carried out by crystal
violet staining according to Ceresa et al. (2019b), with minor
changes. Briefly, biofilms were washed twice and stained with
0.5 ml of the CV solution (0.1%) for 10 min. After the removal of
the excess of dye, CV was dissolved with 0.5 ml of acetic acid (33%
in water). Absorbance of the solutions was measured at 570 nm
(A570) (Victor3VTM, Perkin Elmer, Italy), data were normalized
to blank surfaces (background), and percentages of inhibition







Atreat: absorbance of treated samples
ACTRL: absorbance of controls.
Biofilm Metabolic Activity
The determination of biofilm metabolic activity was carried
out by means of the colorimetric MTT assay according to
Ceresa et al. (2019b), with minor changes. Briefly, biofilms
were washed twice and, then, dipped in 0.5 ml of MTT
working solution [0.075% MTT (Scharlab, Barcelona, ES)
solution supplemented with 0.1% glucose (Biolife, Monza,
IT) and 10 µM menadione (Sigma–Aldrich, St. Louis, MO,
United States)]. After 30 min of incubation at 37◦C in
static conditions, MTT solution was removed and formazan
crystals formed by metabolic active cells within biofilms were
dissolved with 0.5 ml of the lysis solution [dimethyl sulfoxide
(DMSO)/0.1 M glycine buffer (pH 10.2) solution (7:1)]. The
A570 of the solutions was measured, data were normalized
to background, and percentages of inhibition were calculated
according to formula (1).
Planktonic Cells Metabolic Activity
The metabolic activity of planktonic cells in supernatants
was evaluated by the MTT assay according to Ceresa et al.
(2019b), with minor changes. Briefly, growth media and
washing solutions, from each treated and untreated surface,
were collected after 24, 48, and 72 h. Microbial cells were
harvested by centrifugation at 17,000 r/min for 15 min
and incubated in 0.5 ml of the MTT working solution for
30 min. Afterward, cells were collected by centrifugation at
17,000 r/min for 15 min, MTT solution was removed, and
formazan crystals were dissolved with 0.5 ml of the lysis
solution. The A570 of the solutions was measured and data were
normalized to background.
Quantification of Viable Sessile Cells
The number of microbial cells forming the multi-species
biofilms was determined by the spread plate method as
described in Ceresa et al. (2015). Briefly, after two washings,
biofilms were detached from silicone surfaces and broke
up by four cycles of sonication (30 s) and stirring (30 s).
The obtained suspensions were serially diluted in PBS
and seeded both on Mannitol Salt Agar (MSA, Scharlab,
Barcelona, ES) plates, selective for staphylococcal species, and on
Sabouraud Chloramphenicol Agar (SCA, Scharlab, Barcelona,
ES) plates, selective for fungal species. After 24 h at 37◦C,
the colonies were counted and the number of C. albicans,
S. aureus, or S. epidermidis cells within the polymicrobial
biofilm was quantified.
Anti-adhesive Assay
Silicone-elastomeric discs surface coating with the BSs was
carried out as described by Papa et al. (2015), with minor
changes. Briefly, a volume of 20 µl of BS solutions (rhamnolipid
R89BS: 2 mg/ml; lipopeptide AC7BS: 2 mg/ml; sophorolipid
SL18: 8 mg/ml) or 20 µl of PBS as control, were deposited
on the silicone surfaces. SEDs were then placed under laminar
flow to allow complete drying and, subsequently, moved into
48-well plates. The discs were filled with 0.5 ml of the dual-
species suspensions (C. albicans at the concentration of 106
CFU/ml and Staphylococcus spp. at the concentration of 107
CFU/ml in RPMI +2%G) and incubated at 37◦C for 4 h.
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The quantification of cells attached on SEDs was carried out
using crystal violet staining as reported in Section “Biofilm
Biomass.” All experiments were carried out in quadruplicate
and repeated twice.
Cell Surface Hydrophobicity and
Membrane Permeability Changes by BSs
in Soluble Form
Cell Surface Hydrophobicity
Bacterial and fungal suspensions were prepared in PBS to obtain
an optical density (OD) at 600 nm, respectively, of 0.5 and 0.4
and treated with BSs (final concentration R89BS—0.05 mg/ml,
AC7BS—0.5 mg/ml) at 37◦C for 1 h at 150 r/min. Untreated
suspensions were taken as control. Cell hydrophobicity was
measured by microbial adherence to hexadecane (Scharlab,
Barcelona, ES) according to Rosenberg et al. (1980). Microbial
cells were collected by centrifugation at 4000 r/min for 15 min
and resuspended in PUM Buffer, pH 7.1 (22.2 g K2HPO4·3H20,
7.26 g KH2PO4, 1.8 g urea, 0.2 g MgSO4·7H20 and distilled
water to 1 l). One milliliter of hexadecane was mixed to
4 ml of cell suspensions in a glass tube at high speed for
2 min and equilibrated for 10 min. Afterward, the ODs of
the initial cell suspensions and aqueous phases were measured
at 550 nm (Genova Plus, Jenway, United Kingdom) and cell







Bacterial and fungal suspensions were prepared in PBS to obtain
an OD at 600 nm, respectively, of 0.5 and 0.4 and treated with BSs
(final concentration: R89BS—0.05 mg/ml, AC7BS—0.5 mg/ml)
at 37◦C for 1 h at 150 r/min. Untreated suspensions were
taken as control. Cell membrane permeability was evaluated by
checking crystal violet enhanced penetration. Cells were collected
by centrifugation at 4000 r/min for 15 min and resuspended
in PBS containing crystal violet (10 µg/ml) and incubated at
37◦C at 150 r/min for 20 min. Afterward, cells were collected by
centrifugation at 4000 r/min for 15 min and the absorbance (A)
of the solutions was measured at 590 nm (Genova Plus, Jenway,
United Kingdom). The percentage of crystal violet uptake was
estimated using the following formula:(
Asample
Ainitial crystal violet solution
)
× 100 (3)
Experiments were performed in triplicate and repeated
three times.
Biofilm Architecture
The micromorphology and architecture of multi-species biofilm
on SEDs was visualized using the scanning electron microscope
(SEM) Quanta 200F FEG (Fei, Eindhoven, Netherlands)
in high-vacuum mode. Samples were prepared for SEM
imaging according to Ceresa et al. (2019b), with minor
changes. Briefly, after two washings, biofilms were fixed
in 2.5% glutaraldehyde, washed twice in distilled water,
dehydrated in a graded ethanol series, and coated with a
10 nm layer of gold with a sputter coater (Emitech K500X,
Quorum Technologies, Laughton, United Kingdom). A set
of representative images at a magnification of 500×, 1000×,
2000×, and 4000× were obtained from untreated (controls)
and pre-coated SEDs with rhamnolipid R89BS or sophorolipid
SL18 and incubated with either C. albicans–S. epidermidis
or C. albicans–S. aureus at 24, 48, and 72 h. Secondary
electron signal was collected to investigate structural details
of microbial cells and extracellular matrix on the biofilm.
The primary beam energy was set to 5 keV to minimize
damage to the organic structures. Possible artifacts due to
the sample preparation process were considered according
to indications provided by Hrubanova et al. (2018) and
previous experience performed in imaging microbial biofilm
formed in vitro on medical devices (Tessarolo et al., 2007;
Signoretto et al., 2013).
Biocompatibility of BS-Coated Silicone
Discs
The in vitro biocompatibility of BSs-coated discs was evaluated
in 48-well plates by the MTT assay (Ceresa et al., 2019a).
Spontaneously immortalized human skin keratinocyte—HaCaT
cells (104 cells/well) were seeded in Dulbecco’s Modified
Eagle’s Medium (DMEM) high glucose (EuroClone, Milan, IT)
supplemented with 4% FBS (EuroClone, Milan, IT), L-glutamine
200 nM (EuroClone, Italy) and 1% Pen/Strep (EuroClone,
Milan, IT), and incubated at 37◦C in 5% CO2. After 24 h,
growth medium was removed and replaced with the eluates
obtained from BSs-coated SEDs after static release at 37◦C
for 24 h. Negative control consisted in cells treated with
0.5% Triton X, whereas positive control was represented
by cells w/o any treatment. Fifty microliters of the MTT
solution (5 mg/ml) was added into each well. Plates were then
incubated for 24 and 72 h at 37◦C. Formazan crystals were
dissolved with 200 µl of 0.05 M HCl/isopropanol (50:1) and
A570 was measured at the two time points. The percentage





Asample: absorbance of BSs or CTRL—samples
ACTRL+: absorbance of positive controls.
Experiments were performed in triplicate and repeated twice.
Data Analysis and Statistics
All analyses and graphics were performed using the statistical
program R, 3.6.2 (R Core Team, 2019). One-way ANOVA
was applied to compare mono- and dual-species biofilms.
Two-way ANOVA followed by Tukey post hoc test was
used to investigate the anti-biofilm activity of BSs on dual-
species biofilms and the metabolic activity of planktonic
cells. To estimate log10 CFU/disk from colony counts, the R
package dupiR was used (Comoglio et al., 2013). Differences
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in the percentage composition of dual-species biofilms were
investigated by two-sample t-test for equality of proportions
with continuity correction. Two-sample t-test was performed
to evaluate the significance of data in hydrophobicity and
membrane permeability assays. One-way ANOVA followed by
Tukey post hoc test was performed to evaluate the significance
of data in the biocompatibility assay in comparison to positive
and negative controls. Differences were considered statistically




Mono- and dual-species biofilms of C. albicans–Staphylococcus
spp. were grown on polystyrene (Figure 1) and on silicone
surfaces (Figure 2) up to 72 h. Biofilm biomass and biofilm
metabolic activity were quantified at 24, 48, and 72 h. C. albicans–
S. aureus biomass and metabolic activity were higher than
those of the two individual species both on polystyrene and
on silicone at all incubation times (p < 0.001). Concerning
C. albicans–S. epidermidis, biomass and metabolic activity
were always higher than those observed for the individual
species, on both surfaces, up to 48 h (p < 0.001). On the
contrary, at 72 h, biomass and metabolic activity of dual-species
biofilms were lower than those observed for S. epidermidis
biofilms, with the exception of metabolic activity on polystyrene
(p < 0.001).
AC7BS and R89BS were selected to perform the co-
incubation assays as they were previously reported as not
cytotoxic versus MRC5 cells monolayers at the concentrations
active against biofilm (Ceresa et al., 2018, 2019b). On the
contrary, SL-18 was not included in this assay since it was
previously detected as cytotoxic when used in soluble form at
concentrations active against C. albicans and S. aureus single
species biofilms (Ceresa et al., 2020). Increasing concentrations
of lipopeptide AC7BS (0.125–0.5 mg/ml) and rhamnolipid
R89BS (0.0125–0.05 mg/ml) were tested and the minimum
concentration of BSs that counteracted single-species biofilms
formation on polystyrene by at least 80% (inhibition level
threshold) was identified (Figure 3). In general, the formation
of C. albicans and S. aureus biofilms was reduced in a
concentration-dependent manner by the two BSs while the
formation of S. epidermidis biofilm was effectively inhibited
(≥80%) only by rhamnolipid R89BS (Figure 3A). In particular,
the three mono-species biofilms were inhibited by about 87%
by rhamnolipid R89BS at a concentration of 0.05 mg/ml.
Concerning lipopeptide AC7BS (Figure 3B), the threshold
inhibition level was reached at a concentration of 0.5 mg/ml
only for C. albicans and S. aureus biofilms (82%) but not for
S. epidermidis, which had a maximum inhibition of only 27%.
For this reason, this BS was excluded from the subsequent
anti-biofilm assays against C. albicans–S. epidermidis dual-
species biofilms.
The boxplot in Figure 4 shows the effect of rhamnolipid
R89BS and lipopeptide AC7BS against C. albicans–S. aureus and
of R89BS against C. albicans–S. epidermidis biofilm formation
up to 72 h. In general, as confirmed by two-way ANOVA
and Tukey post hoc test, for each co-culture, biofilm formation
on polystyrene was significantly dependent on BSs treatment
(p < 0.001) and incubation time (p < 0.001). Regardless of the
two strain combinations involved in the dual-species biofilm
development, biofilm biomass (Figures 4A,D) and metabolic
activity (Figures 4B,E) were equally inhibited by the BSs. The
anti-biofilm activity of rhamnolipid R89BS was stable up to 72 h,
while, for lipopeptide AC7BS, a slight reduction was detected
between 24 and 72 h. In particular, as observed in Table 1,
rhamnolipid R89BS proved to be the most effective BS for
the inhibition of C. albicans–S. aureus biofilm growth and an
excellent agent for the prevention of C. albicans–S. epidermidis
biofilm formation, with mean percentages of reduction of 94%
(C. albicans–S. aureus) and 95% (C. albicans–S. epidermidis),
after 72 h co-incubation. In addition, to define whether part of
the observed effect was the result of an antimicrobial activity
of the BSs, the metabolic activity of planktonic cells in the
supernatants was assessed (Figures 4C,F). The absorbance values
of the cell supernatants co-incubated with BSs were significantly
higher in comparison to the controls (p < 0.001) suggesting that,
in the treated wells, cells existed in a planktonic state rather
than by forming a biofilm. However, in the case of C. albicans–
S. aureus co-cultures, the lower absorbance values observed
in the rhamnolipid R89BS-treated wells compared to those of
the lipopeptide AC7BS-treated wells (p < 0.001), suggested an
antimicrobial activity of the rhamnolipid (Figure 4C).
The results of BSs pre-coating on SEDs further confirmed
the inhibitory activity of these natural microbial molecules
against the formation of C. albicans–S. aureus (rhamnolipid
R89BS, lipopeptide AC7BS, sophorolipid SL18) and C. albicans–
S. epidermidis (rhamnolipid R89BS, sophorolipid SL18) mixed
biofilms (Figure 5). As previously observed in co-incubation
conditions, for each co-culture, the development of biofilms on
silicone surfaces was significantly dependent on BSs treatment
(p < 0.001) and incubation time (p < 0.001). Biofilm biomass
(Figures 5A,D) and metabolic activity (Figures 5B,E) were
equally inhibited on all BSs-coated discs (SEDs). Concerning the
dual-species biofilms of C. albicans–S. aureus, the anti-biofilm
activity of rhamnolipid R89BS- and sophorolipid SL18-coated
SEDs was stable up to 72 h, while a slight reduction of the efficacy
of lipopeptide AC7BS-coated SEDs was observed during this
time. The anti-biofilm activity of rhamnolipid R89BS coating was
stable also for C. albicans–S. epidermidis mixed biofilms, while
that of sophorolipid SL18-coated SEDs slightly decreased over
time. In general, starting from 48 h of incubation, the surface
treatment of silicone with rhamnolipid R89BS proved to be the
most effective in counteracting the growth of both polymicrobial
biofilms. In particular, after 72 h, average inhibitions of 93 and
90% against C. albicans–S. aureus and C. albicans–S. epidermidis
biofilms were found, respectively. Table 2 shows the percentages
of biomass and metabolic activity inhibition at the different
time-points. To exclude that the observed activity was due to
an antimicrobial action of the BSs, the metabolic activity of
the planktonic cells in the wells was evaluated (Figures 5C,F).
As observed in co-incubation conditions, the absorbance values
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FIGURE 1 | Mono- and dual-species C. albicans–Staphylococcus spp. biofilm formation on polystyrene. The ability of microbial strains to form biofilms was
evaluated at 24, 48, and 72 h by biofilm biomass (A,C) and biofilm metabolic activity (B,D) quantification.
of the supernatants of the BSs-coated silicone discs were
significantly higher than those obtained for the corresponding
controls (p < 0.001). Conversely, no significant variations were
found between the absorbance values of planktonic cells recorded
for the different BSs treatments (p > 0.05).
In addition, to evaluate whether the tested BSs exhibited their
anti-biofilm action in equal proportions on the single species
forming the polymicrobial biofilms on the silicone surfaces, the
number of cells of C. albicans, S. aureus, and S. epidermidis was
determined on selective media for both control and coated discs
(Supplementary Tables 1, 2) and the percentage compositions
were calculated (Tables 3, 4). In general, at all incubation times,
biofilms on the control discs mainly consisted of bacterial cells
(98.6–99.8%) and only for a small percentage of the yeast cells
(0.2–1.4%). In particular, the yeast cells were present in a major
proportion in C. albicans–S. aureus biofilms (Table 3) than in
C. albicans–S. epidermidis (Table 4). Interestingly, at 24 h, the
presence of BSs on the silicone surface was associated with a
significant increase in the yeast species percentage compared
to that observed on the controls (p < 0.001). However, this
value decreased over time and returned to levels similar to those
observed for the controls.
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FIGURE 2 | Mono- and dual-species C. albicans–Staphylococcus spp. biofilm formation on silicone discs. Biofilms were evaluated in terms of biofilm biomass (A,C)
and biofilm metabolic activity (B,D) at 24, 48, and 72 h.
Finally, to assess the activity of BSs coating on SEDs
on the early phases of biofilm formation (adhesion phase),
the amount of C. albicans–S. aureus and C. albicans–
S. epidermidis adherent cells was evaluated after 4 h incubation
by means of the CV method (Figure 6). Similarly, to biofilm
formation, microbial cells adhesion to silicone surfaces was
also significantly dependent on BSs treatment (p < 0.001).
Concerning C. albicans–S. aureus, the highest anti-adhesive
activity was observed for rhamnolipid R89BS (71%), followed
by sophorolipid SL18 (64%) and lipopeptide AC7BS (51%). As
to C. albicans–S. epidermidis, rhamnolipid R89BS coating
proved to be the most effective with an inhibition of
adhesion of 62% while for sophorolipid SL18 showed a
54% inhibition.
Cell Surface Hydrophobicity and
Membrane Permeability Changes by BSs
in Soluble Form
In order to evaluate the possible effect of BSs on the
tested opportunistic pathogens in co-incubation conditions, cell
surface hydrophobicity (CSH) and membrane permeability were
assessed. As shown in Figure 7A, after 1 h incubation with R89BS
and AC7BS, CSH and membrane permeability of C. albicans,
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FIGURE 3 | Activity of BSs in soluble form on C. albicans, S. aureus, and S. epidermidis biofilm formation. The anti-biofilm activity of AC7BS (A) and R89BS (B) was
evaluated in co-incubation conditions by the determination of biofilm biomass.
S. aureus, and S. epidermidis were different from the untreated
controls. BSs treatment induced a significant modification of
CSH for all the tested strains (p < 0.05). In particular, it resulted
in a decrease of CSH both for bacterial and fungal cells. Bacterial
CSH decreased from 99% (mean percentage for untreated control
samples) to values ranging from 38 to 71% for BSs treated
samples. Fungal CSH in comparison was reduced from 44%
(mean percentage for control samples) to values ranging from 31
to 37% for BSs treated samples. The changes of CSH induced by
BSs were related to the microbial strain: in particular, S. aureus
was the most susceptible to cell hydrophobicity changes, followed
by S. epidermidis and C. albicans. The treatment with BSs also
altered cell membrane permeability for all the tested strains
(p < 0.05) (Figure 7B). In particular, BSs induced an increase in
crystal violet uptake by bacterial cells from 46% (mean percentage
for untreated control samples) to values ranging from 54 to 74%
and a slight increase in the case of fungal cells from 53% (mean
percentage for untreated control samples) to values ranging from
56 to 59%. Again, the changes of membrane permeability induced
by BSs were related to the microbial strain: in particular, S. aureus
and S. epidermidis were more susceptible to BSs than C. albicans.
Scanning Electron Microscopy of
Multi-species Biofilms on SEDs
Scanning electron microscopic images presenting the features of
the biofilm formed on untreated (controls) and pre-coated SEDs
with rhamnolipid R89BS and sophorolipid SL18 at the longest
incubation time are presented in Figure 8. The SEM investigation
showed the presence of both fungal hyphae and coccoid bacteria
adhering to the surface of all samples. In general, there was
a more pronounced spatial correlation between S. aureus and
C. albicans (Figures 8A,C,E) than between S. epidermidis
and C. albicans (Figures 8B,D,F), irrespective of the surface
treatment. More specifically, S. aureus was prevalently found in
close contact with fungal hyphae, almost completely covering the
Candida mycelium at 72 h in control SEDs (Figure 8A), while
S. epidermidis never realized a full coating of the C. albicans
structures (Figure 8B) and was more prone to adhere directly to
the SEDs surface (Figure 8D).
In agreement with the results obtained from quantitative
tests of biofilm biomass performed on corresponding samples,
untreated controls showed a well-structured dual-species
biofilm at each time-points, having a more three-dimensional
arrangement and a thicker appearance at longer incubation
times (Figures 8A,B). A similar increasing trend in the number
of cells at the surface was also observed for rhamnolipid R89BS
and sophorolipid SL18 pre-coated SEDs. However, the number
of microbial cells at the treated surface was drastically reduced in
respect of controls and the large majority of the sample surface
was free of cells or presented small clusters with few three-
dimensional microbial aggregates at 24 and 48 h (Supplementary
Figures S1, S2). This was also the case for S. aureus and
C. albicans dual-species biofilm at 72 h (Figures 8C,E), but not
for S. epidermidis and C. albicans dual-species biofilm where
only a minor portion of the treated surface was free of cells
(Figure 8D) or mainly fully covered (Figure 8F). At 72 h,
some differences in C. albicans–S. epidermidis biofilms were
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FIGURE 4 | Anti-biofilm activity of BSs in soluble form on C. albicans–S. aureus and C. albicans–S. epidermidis biofilm formation. The anti-biofilm activity of BSs was
evaluated in co-incubation conditions in terms of biofilm biomass (A,D) and biofilm metabolic activity (B,E). The viability of planktonic cells (C,F) was measured by
the metabolic activity assay.
also noted between rhamnolipid R89BS and sophorolipid SL18
pre-coated discs, with the latter presenting areas showing a
mature biofilm (Figure 8F), although less structured and thick
than the controls (Figure 8B). Rhamnolipid R89BS pre-coated
SEDs showed only minor portions of the disc surface still free of
microorganisms (Figure 8D).
Cytotoxicity of BSs-Coated Silicone
Discs
No cytotoxic effect was detected on spontaneously immortalized
human skin keratinocyte when exposed for 24 h to the BSs-coated
SEDs eluates obtained from static release conditions. In fact, at
this time-point, the viability of HaCat cells was comparable to
positive controls (p > 0.05), independently to the type of BS
involved in the coating procedure (Supplementary Figure S3A).
After 72 h of cells exposure to the eluates, cell viability slightly
decreased to values ranging from 92% for SL18 to 78% for
R89BS (Supplementary Figure S3B) but was always above the
limit (70%) according to the ISO 10993-5 standard (Xian, 2009;
Rodríguez-López et al., 2020).
DISCUSSION
Microbial colonization and biofilm formation on medical devices
represent one of the major challenges in infection control
(Percival et al., 2015; Wang et al., 2017; Khatoon et al., 2018).
Biofilms protect microbial cells from antimicrobials and the
immune system of hosts and, in most cases, this may lead to the
dysfunction of the devices and eventual removal (Percival et al.,
2015; Khatoon et al., 2018; Sharma et al., 2019).
Nowadays, C. albicans is considered as the prevailing fungal
pathogen responsible for severe hospital-acquired infections
and has also been reported to form polymicrobial biofilms in
coexistence with bacterial species such as S. aureus, S. epidermidis,
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TABLE 1 | Inhibition percentages of dual-species C. albicans–S. aureus and
C. albicans–S. epidermidis biofilm formation on polystyrene in co-incubation
assays. The anti-biofilm activity of BSs in soluble form was detected by CV (biofilm
biomass) and MTT assays (biofilm metabolic activity).
Strains Assessment Time (h) Treatment
AC7BS (%) R89BS (%)
C–Sa Biofilm biomass 24 96.4 95.6
48 85.8 96.2
72 84.3 94.3
Biofilm metabolic activity 24 95.0 96.4
48 89.2 96.1
72 83.0 93.5
C–Se Biofilm biomass 24 − 96.5
48 − 96.5
72 − 95.7
Biofilm metabolic activity 24 − 95.1
48 − 94.6
72 − 95.3
C–Sa, C. albicans–S. aureus;
C–Se, C. albicans–S. epidermidis;
−, not evaluated.
P. aeruginosa, and Streptococcus spp. (Liu et al., 2019). These
microbial pathogens are well known for their ability to form
persistent biofilms on biotic and abiotic surfaces such as
tissues, organs, and medical-devices, including dentures, voice
prostheses, implants, endotracheal tubes, feeding tubes, and most
frequently, catheters (Carolus et al., 2019; Liu et al., 2019).
The existence of these multi-species communities makes
the challenge against biofilms even more complex because
it does not only require effective antimicrobials against all
pathogenic microorganisms present in the microbial community,
but limits the effectiveness of to date-developed species-specific
biofilm targeting strategies (Koo et al., 2017). Based on these
considerations, numerous researchers have aimed their studies
at identifying new and effective approaches to counteract
polymicrobial biofilms, both in terms of inhibition of microbial
adhesion and disruption of mature biofilms (Villa and Cappitelli,
2013). Among these, the use of new antimicrobial peptides has
been suggested as a promising treatment against fungal/bacterial
polymicrobial biofilms (Qu et al., 2016; de Alteriis et al., 2018;
Gupta et al., 2019). Through a different mechanism of action,
these molecules can cause microbial death, inhibit bacterial
growth, and compromise biofilm formation and architecture.
Weiland-Bräuer et al. (2019) identified, in the metagenome-
derived bacterial quorum quenching (QQ), proteins QQ-5 and
QQ-7 as an effective strategy to prevent C. albicans and
S. epidermidis biofilm formation, by inhibiting C. albicans
yeast-to-hyphae transition and inducing the expression of the
icaR gene, thus repressing the synthesis of polysaccharide
intercellular adhesion (PIA).
A further strategy currently proposed to treat C. albicans–
S. aureus infections is based on combined therapies of existing
antimicrobials or treatments with natural molecules, such as
plant extracts or essential oils, alone or in combination with
antibiotics or antifungals (Budzynska et al., 2017; Scaffaro et al.,
2018; Tan et al., 2019).
In this scenario, BSs effectively appear to be promising
new candidates for biofilm inhibition in the biomedical field
due to their interesting antimicrobial, anti-adhesive properties
(Banat et al., 2010; Rodrigues and Teixeira, 2010; Fracchia et al.,
2019; Naughton et al., 2019). These molecules, in fact, are able
to counteract effectively biofilms by decreasing microbial cells
viability and by reducing microbial adhesion (Satpute et al., 2016;
Fracchia et al., 2019; Paraszkiewicz et al., 2019; Naughton et al.,
2019). When BSs bind to cell wall surface, they may form a film
that changes the wettability and the surface energy of the cell
leading to severe changes in its hydrophobicity and increasing
its permeability by the release of LPS and the formation of
transmembrane pores. When applied as coating agents, BSs
interfere with microbial adhesion and limit biofilm formation
altering the chemical and physical properties of the surfaces
(e.g., reduction of roughness and hydrophobicity or increase of
wettability) on which biofilms develop (Rodrigues et al., 2006;
Quinn et al., 2013; Satpute et al., 2019).
In this study, we demonstrated the ability of different BSs to
inhibit the formation of fungal and bacterial dual-species biofilms
for up to three days in both co-incubation and pre-coating assays.
One lipopeptide (AC7BS) and two glycolipids (R89BS and SL18)
were tested. As observed by the positive ESI–MS analysis, AC7BS
is composed of surfactin (98%) and fengycin (2%) homologs
(Ceresa et al., 2016). Surfactin family members are represented by
C13, C14, and C15 homologs whereas fengycin family members
are represented by two main fengycin isoforms corresponding to
C17 fengycin A and C17 fengycin B. The negative electrospray
ionization (ESI) MS analysis of R89BS extract showed the
presence of mono- (75%) and di- (25%) rhamnolipid homologs.
Mono-rhamnolipid family members are represented by C10–
C10, C8–C10, and C10–C12 homologs whereas di-rhamnolipid
family members by C10–C8, C10–C10, and C10–C12 homologs
(Ceresa et al., 2019b). Sophorolipid SL18 is a mixture of lactonic
congeners (Ceresa et al., 2020). The fungal strain C. albicans and
the bacterial strains S. aureus and S. epidermidis were selected
as they represent a major cause of medical device associated
infections due to their ability to adhere to biomaterials and form
antimicrobial-resistant multispecies biofilms (Arciola et al., 2005;
von Eiff et al., 2006; Sardi et al., 2013; Carolus et al., 2019).
The experiments reported in this study were carried out
using culture media and growth conditions that support
the reproducible development of well-structured dual-species
biofilms, as demonstrated by the high values of biofilm biomass
and cell metabolic activity detected for the controls and by SEM
images of control biofilms. BSs were tested in solution or coated
on silicone surfaces by physical absorption. Dual-species cultures
were evaluated by the quantification of different parameters:
biomass, metabolic activity, and number of viable cells. The
microstructure of dual-species biofilms on treated and untreated
silicone was also characterized by SEM analysis.
The lipopeptide AC7BS and the rhamnolipid R89B, tested in
soluble form in co-incubation conditions, showed a significant
inhibitory activity against the formation of dual-species biofilms
of C. albicans and Staphylococcus spp. determining high levels
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FIGURE 5 | Anti-biofilm activity of the BSs coated silicone discs. The efficacy of the surface treatments was evaluated in terms of biofilm biomass (A,D) and biofilm
metabolic activity (B,E). The viability of planktonic cells was measured by the metabolic activity assay (C,F).
of reduction, both in terms of total biomass and metabolic
activity with inhibitions ranging from 84 to 96% at 72 h.
These findings suggest a potential applicability of these BSs as
components of pharmaceutical formulations, such as injectable
scaffolds or hydrogels enriched with antimicrobial or anti-biofilm
agents useful in wound healing. Similar conclusions were also
reached by for better wound healing when microbial glycolipid
BS-containing ointment was used as a transdermal substitute
treatment process (Gupta et al., 2017).
Coating of silicone surfaces with lipopeptide AC7BS,
rhamnolipid R89BS, and sophorolipid SL18 was as much
beneficial, further confirming the inhibitory activity of these
natural molecules against the formation of both dual-species
biofilms, with percentages of inhibition at 72 h ranging from 77
to 93%. R89BS in particular was found to be the most effective
BS in inhibiting both dual-species biofilms on both surfaces.
Both rhamnolipids and sophorolipids have also shown to be
active against other multi-species cultures (Diaz De Rienzo et al.,
2016). They observed using the BioFlux flow through conditions,
that a combination of caprylic acid (0.01% v/v) and rhamnolipids
(0.04% v/v) caused the disruption of single and mixed biofilms
for P. aeruginosa and S. aureus. Biofilms were also efficiently
dislodged by the combination of rhamnolipids (0.04% v/v) with
sophorolipids (0.01% v/v). Interestingly, these authors observed
that biofilm disruption of S. aureus and mixed cultures was
caused by the anti-biofilm properties of BSs without affecting cell
viability whereas for the P. aeruginosa biofilms, a high rate of
killed cells was observed.
According to the studies conducted so far, in co-incubation
conditions, the anti-biofilm activity of the tested BSs seemed to
be related to a reduction of CSH and thus to a change in cells
ability to adhere to the silicone surface (Elshikh et al., 2016).
For rhamnolipid R89BS, the effect was also partly associated to
its antibacterial activity on staphylococcal cells, as demonstrated
in a previous work (Ceresa et al., 2019b) and confirmed in this
study by the observed decrease of the planktonic cells metabolic
activity and the increase in membrane permeability. On the
contrary, an antifungal effect on C. albicans was not observed
at the tested concentrations, indicating that the antimicrobial
activity of the rhamnolipid is also microorganism dependent as
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TABLE 2 | Inhibition percentages of dual-species C. albicans–S. aureus and
C. albicans–S. epidermidis biofilm formation on BSs treated silicone discs by CV
(biofilm biomass) and MTT assays (biofilm metabolic activity).







C–Sa Biofilm biomass 24 95.1 96.9 95.6
48 90.2 96.7 91.8
72 87.3 94.6 93.1
Biofilm metabolic activity 24 95.6 97.2 95.8
48 90.0 96.3 92.6
72 82.8 92.0 90.3
C–Se Biofilm biomass 24 − 96.1 94.4
48 − 97.7 86.1
72 − 91.0 78.8
Biofilm metabolic activity 24 − 96.5 94.5
48 − 94.1 86.7
72 − 89.8 74.4
C–Sa, C. albicans–S. aureus;
C–Se, C. albicans–S. epidermidis;
−, not evaluated.
observed by Diaz De Rienzo et al. (2016). Lipopeptide AC7BS
was in general less effective in counteracting S. epidermidis
biofilm formation as suggested by the fact that the inhibition
level threshold of 80% was not reached when tested in co-
incubation conditions against single species biofilm. In addition,
CSH assays indicated that S. epidermidis was less susceptible
to cell hydrophobicity changes induced by AC7BS compared to
S. aureus. Moreover, S. epidermidis cell permeability was less
affected in the presence of AC7BS in comparison to rhamnolipid
R89BS. It may be hypothesized that the ability of this strain to
produce a high amount of slime (Arciola et al., 2001; Williams
and Bloebaum, 2010) might have interfered with the activity of
AC7BS in the co-incubation conditions. Furthermore, AC7BS
did not show any antimicrobial activity against S. epidermidis
[Ceresa et al. Biosurfactant-based coatings inhibit fungal and
bacterial biofilm on medical-grade silicone. TERMIS 2017.
Davos, Switzerland, eCM Meeting Abstracts 2017, Collection 2;
TERMIS EU (P821)] whereas, as far as R89BS is concerned,
a MIC99 was detected at 120 µg/mL (Ceresa et al., 2019a)
indicating a higher efficacy of the rhamnolipid against this strain
compared to the lipopeptide.
TABLE 3 | Percentage (%) composition of C. albicans–S. aureus dual-species
biofilms on the surface of silicone discs.
Time (h) Strains Treatment
CTRL (%) AC7BS (%) R89BS (%) SL18 (%)
24 C. albicans 1.4 4.5 4.9 4.0
S. aureus 98.6 95.5 95.1 96.0
48 C. albicans 1.4 1.6 1.7 0.9
S. aureus 98.6 98.4 98.3 99.1
72 C. albicans 1.3 1.4 0.3 0.5
S. aureus 98.7 98.6 99.7 99.5
TABLE 4 | Percentage (%) composition of C. albicans–S. epidermidis
dual-species biofilms on the surface of silicone discs.
Time (h) Strains Treatment
CTRL (%) R89BS (%) SL18 (%)
24 C. albicans 0.2 1.0 0.6
S. epidermidis 99.8 99.0 99.4
48 C. albicans 0.2 0.2 0.1
S. epidermidis 99.8 99.8 99.9
72 C. albicans 0.2 0.2 0.2
S. epidermidis 99.8 99.8 99.8
When applied on silicone surfaces as coating agents, BSs
effects were mostly related to their anti-adhesive properties.
Surface physicochemical characterization of BSs-coated discs
showed an increased level of wettability, i.e., a reduction of
hydrophobicity (static contact angle for AC7BS-coated SEDs:
94.4◦ ± 10.0◦; dynamic contact angle for R89BS-coated SEDs:
84.4◦ ± 2.2◦ (advancing) and 72.2◦ ± 2.5◦ (receding)), in
comparison to control discs (112◦ ± 5◦) (Ceresa et al., 2016,
2019b). In addition, concerning R89BS, the anti-biofilm effect
in the pre-coating conditions was not due to an antimicrobial
activity, as indicated by the fact that planktonic cells metabolic
activity was similar to that observed in the presence of the other
BSs, thus suggesting that the amount of R89 deposited on the
silicone surface was largely below the biocidal concentration
for staphylococci.
The impact of the BSs pre-coating in the formation of dual-
species biofilm on the surface of medical grade silicon was also
observed by SEM inspection. R89BS and SL18 almost completely
prevented the attachment of the dual-species biofilms up to 48 h,
and a clear reduction in the amount of biofilm with respect to
controls was still evident at 72 h of incubation.
Differences in the cell arrangements and, more specifically, in
the relative spatial distribution of cocci and yeasts were noted
between C albicans–S aureus and C. albicans–S. epidermidis,
whereas no influence on the inter-species spatial association
was observed by comparing BS-coated and untreated silicone
surfaces. A stronger association between the fungal and bacterial
cells was observed in the C albicans–S aureus biofilm. As
previously reported by Harriott and Noverr (2009), S. aureus
mainly formed microcolonies on the surface of the biofilm, with
C. albicans serving as the underlying scaffolding. Compared to
S. epidermidis, S. aureus was not as effective in forming biofilms
on abiotic surfaces, requiring precoating and supplementation
of nutrients (Cassat et al., 2007). C. albicans was shown
to play an essential role in producing extracellular matrix
that facilitates S. aureus adhesion and sessile microcolonies
formation (Harriott and Noverr, 2009). The C. albicans–
S. epidermidis biofilm was characterized by a more open hyphal
network and the association of S. epidermidis cells with the
fungal structures was less marked. S. epidermidis cells were
found beneath and above the yeast cells and hyphal layers
and the Staphylococci cells were clearly adherent to both
morphological forms of the fungus as previously reported by
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FIGURE 6 | Anti-adhesive activity of the BSs coated silicone discs. The efficacy of the BSs surface treatment was evaluated in terms of C. albicans–S. aureus (A)
and C. albicans–S. epidermidis (B) adherent cells after 4 h of incubation.
other authors (Adam et al., 2002). Anyway, the adhesion and
microcolonies formations of S. epidermidis on the surface of
the silicone samples were frequently noted also in absence of
fungal cells, possibly due to their higher ability to produce
extracellular matrix.
Apparent discrepancies between results from the biofilm
biomass evaluation (Table 2) and the corresponding SEM images
(e.g., Figures 8C,D differ significantly despite similar reduction
rates) are due to differences in the corresponding controls.
Despite SEM present a similar surface coverage of the controls,
absorbance data indicate different biofilm biomass of the controls
(Figure 2), most probably due to different biofilm thickness, not
properly appreciable at SEM. Confocal laser scanning microscopy
analysis carried out in a previous work demonstrated that the
silicone coating with AC7BS expressed a detectable capacity
in controlling Candida biofilm thickness after 48 h incubation
(Ceresa et al., 2018).
No clear effect on the production of extracellular matrix
by Candida was noted following the silicone precoating with
R89BS or SL18. Indeed, the comparative analysis of Candida
biofilm on the pre-coated discs with the controls did not
show major differences in the amount of extracellular matrix.
However, it has to be considered that SEM imaging in high
vacuum brought to significant collapse of the matrix volume,
limiting the sensitivity of this technique in revealing small
changes in the matrix.
The strong association of S. aureus and C. albicans was
indeed found in both untreated controls and pre-coated
surfaces demonstrating the ability of Candida to provide an
anchoring support for S. aureus. The anti-biofilm effect of
the tested BSs could be therefore mainly related to the anti-
adhesive properties rather than to a change in the microbial
phenotypes including a reduction of the extracellular matrix
production as reported by Gupta et al. (2019) using cholic acid-
peptide conjugates.
Furthermore, the use of R89BS and SL18 as coating agents
did not result in a clear modification of the C. albicans
hyphal morphology. However, it would be interesting to
evaluate in future whether these BSs, both in their soluble
and coated form, are able to cause a delay on Candida yeast-
to hyphal transition at the initial phases of biofilm formation,
thus as reported for sophorolipids from Starmerella bombicola
MTCC1910 (Haque et al., 2016) and a Lactobacillus rhamnosus
(Tan et al., 2017).
Another important aspect is the biocompatibility of the
AC7BS-, R89BS-, and SL18-coated silicone discs. It has
been previously demonstrated that at concentrations lower
than or equal to 0.2 mg/ml for R89BS and 0.5 mg/ml for
AC7BS were not cytotoxic for MRC5 cells monolayers (Ceresa
et al., 2018, 2019b). In this work, additional evaluations
revealed no or negligible cytotoxicity on HaCaT cells when
exposed to the BSs-coated discs eluates for up to 72 h,
paving the way for further investigation toward future
in vivo applications.
CONCLUSION
In the present work, the activities of different BSs against
yeast and bacterial biofilms were demonstrated through using
a polymicrobial biofilm model able to support the growth
of bacterial–fungal biofilms. The tests were conducted both
under co-incubation and pre-coating conditions to evaluate,
on the one hand, the inhibitory effect of BSs in solution
against the polymicrobial biofilms and, on the other hand,
the effectiveness of BSs as coating agents of medical devices
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FIGURE 7 | Changes in cell surface hydrophobicity and membrane permeability induced by soluble BSs. Cell surface hydrophobicity (A) and membrane permeability
(B) of C. albicans, S. aureus, and S. epidermidis treated with BSs in soluble form (co-incubation conditions), compared to control samples.
to limit microbial infection. BSs successfully limited the
formation of polymicrobial biofilms up to 3 days under both
experimental conditions.
The obtained results, together with the non-toxic nature
of BSs at the tested concentrations and the biocompatibility
of BSs-coated discs, further support the idea of a possible
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FIGURE 8 | Scanning electron microscopy images of the dual-species biofilms formed on the silicone discs surface at 72 h. C. albicans–S. aureus on the left column
and C. albicans–S. epidermidis on the right column. Different surface pre-coating treatments are presented: untreated controls (top row), rhamnolipid R89BS (middle
raw), and sophorolipid SL18 (bottom row) treated discs. Insets present a lower magnification of the corresponding image to appreciate both macrostructural
arrangement of the biofilm on the surface and micro-structural architecture of the two species in each biofilm sample. Original magnification: 4000x (1000x for the
insets).
applicability of these natural molecules in the biomedical
field. In particular, BSs coating might be a promising
strategy, supporting preventative infection measures and
antimicrobial therapy, to reduce implant colonization and
mitigate infections, thus prolonging the lifetime of implantable
medical devices.
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